GlaxoSmithKline plc (the 'Company')
Transaction notification
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Ms E Walmsley |
|||
| b) |
Position/status |
Chief Executive Officer |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GlaxoSmithKline plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
| b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£14.0080 |
956 |
|
||
|
|
£14.0080 |
769 |
|
||
|
|
£14.0080 |
640 |
|
||
|
|
|
|
|
||
| d) |
Aggregated information
|
2,365 |
|||
|
Aggregated volume Price |
£14.0080 |
||||
| e) |
Date of the transaction |
2021-10-11 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Mr I Mackay |
|||
| b) |
Position/status |
Chief Financial Officer |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GlaxoSmithKline plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
| b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£14.0080 |
519 |
|
||
|
|
£14.0080 |
443 |
|
||
|
|
|
|
|
||
| d) |
Aggregated information
|
962 |
|||
|
Aggregated volume Price |
£14.0080 |
||||
| e) |
Date of the transaction |
2021-10-11 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Dr H Barron |
|||
| b) |
Position/status |
Chief Scientific Officer and President, R&D |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GlaxoSmithKline plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
|||
| b) |
Nature of the transaction |
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 7 October 2021 on ADSs held in the Company's Deferred Annual Bonus Plan |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
$38.6600 |
557 |
|
||
|
|
$38.6600 |
437 |
|
||
|
|
$38.6600 |
331 |
|
||
|
|
|
|
|
||
| d) |
Aggregated information
|
1,325 |
|||
|
Aggregated volume Price |
$38.6600 |
||||
| e) |
Date of the transaction |
2021-10-11 |
|||
| f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Mr R Connor
|
|||
| b) |
Position/status |
President, Vaccines & Global Health |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GlaxoSmithKline plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
| b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£14.0080 |
250 |
|
||
|
|
£14.0080 |
242 |
|
||
|
|
£14.0080 |
140 |
|
||
|
|
|
|
|
||
| d) |
Aggregated information
|
632 |
|||
|
Aggregated volume Price |
£14.0080 |
||||
| e) |
Date of the transaction |
2021-10-11 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Ms D Conrad |
|||
| b) |
Position/status |
SVP Human Resources |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GlaxoSmithKline plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
| b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£14.0080 |
100 |
|
||
|
|
£14.0080 |
92 |
|
||
|
|
|
|
|
||
| d) |
Aggregated information
|
192 |
|||
|
Aggregated volume Price |
£14.0080 |
||||
| e) |
Date of the transaction |
2021-10-11 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Mr J Ford |
|||
| b) |
Position/status |
Senior Vice President and General Counsel |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GlaxoSmithKline plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
| b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£14.0080 |
142 |
|
||
|
|
£14.0080 |
111 |
|
||
|
|
|
|
|
||
| d) |
Aggregated information
|
253 |
|||
|
Aggregated volume Price |
£14.0080 |
||||
| e) |
Date of the transaction |
2021-10-11 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Mr J Ford |
|||
| b) |
Position/status |
Senior Vice President and General Counsel |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GlaxoSmithKline plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
|||
| b) |
Nature of the transaction |
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 7 October 2021 on ADSs held in the Company's Deferred Annual Bonus Plan |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
$38.6600 |
47 |
|
||
|
|
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction) |
|||
|
Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2021-10-11 |
|||
| f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Ms S Jackson |
|||
| b) |
Position/status |
SVP, Global Communications & CEO Office |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GlaxoSmithKline plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
| b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£14.0080 |
60 |
|
||
|
|
£14.0080 |
56 |
|
||
|
|
|
|
|
||
| d) |
Aggregated information
|
116 |
|||
|
Aggregated volume Price |
£14.0080 |
||||
| e) |
Date of the transaction |
2021-10-11 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Mr B McNamara |
|||
| b) |
Position/status |
CEO, GSK Consumer Healthcare |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GlaxoSmithKline plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
|||
| b) |
Nature of the transaction |
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 7 October 2021 on ADSs held in the Company's Deferred Annual Bonus Plan |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
$38.6600 |
93 |
|
||
|
|
$38.6600 |
80 |
|
||
|
|
$38.6600 |
101 |
|
||
|
|
|
|
|
||
|
|
|
|
|
||
| d) |
Aggregated information
|
274 |
|||
|
Aggregated volume Price |
$38.6600 |
||||
| e) |
Date of the transaction |
2021-10-11 |
|||
| f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Mr L Miels |
|||
| b) |
Position/status |
Chief Commercial Officer |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GlaxoSmithKline plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
| b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£14.0080 |
266 |
|
||
|
|
£14.0080 |
232 |
|
||
|
|
£14.0080 |
173 |
|
||
|
|
|
|
|
||
| d) |
Aggregated information
|
671 |
|||
|
Aggregated volume Price |
£14.0080 |
||||
| e) |
Date of the transaction |
2021-10-11 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Mr D Redfern |
|||
| b) |
Position/status |
Chief Strategy Officer |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GlaxoSmithKline plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
| b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£14.0080 |
237 |
|
||
|
|
£14.0080 |
170 |
|
||
|
|
£14.0080 |
136 |
|
||
|
|
|
|
|
||
| d) |
Aggregated information
|
543 |
|||
|
Aggregated volume Price |
£14.0080 |
||||
| e) |
Date of the transaction |
2021-10-11 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Mr R Simard |
|||
| b) |
Position/status |
President, Pharmaceuticals Supply Chain |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GlaxoSmithKline plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
| b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£14.0080 |
85 |
|
||
|
|
£14.0080 |
120 |
|
||
|
|
£14.0080 |
102 |
|
||
|
|
|
|
|
||
| d) |
Aggregated information
|
307 |
|||
|
Aggregated volume Price |
£14.0080 |
||||
| e) |
Date of the transaction |
2021-10-11 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Ms K Terrell |
|||
| b) |
Position/status |
Chief Digital & Technology Officer |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GlaxoSmithKline plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
|||
| b) |
Nature of the transaction |
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 7 October 2021 on ADSs held in the Company's Deferred Annual Bonus Plan |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
$38.6600 |
118 |
|
||
|
|
$38.6600 |
81 |
|
||
|
|
$38.6600 |
63 |
|
||
|
|
|
|
|
||
| d) |
Aggregated information
|
262 |
|||
|
Aggregated volume Price |
$38.6600 |
||||
| e) |
Date of the transaction |
2021-10-11 |
|||
| f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Mr P Thomson |
|||
| b) |
Position/status |
President, Global Affairs |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GlaxoSmithKline plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
|||
| b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£14.0080 |
138 |
|
||
|
|
£14.0080 |
98 |
|
||
|
|
£14.0080 |
79 |
|
||
|
|
|
|
|
||
| d) |
Aggregated information
|
315 |
|||
| Aggregated volume Price |
£14.0080 |
||||
| e) |
Date of the transaction |
2021-10-11 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
| 1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
| a) |
Name |
Ms D Waterhouse |
|||
| b) |
Position/status |
Chief Executive Officer of ViiV Healthcare |
|||
| c) |
Initial notification/ amendment |
Initial notification |
|||
| 2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
| a) |
Name |
GlaxoSmithKline plc |
|||
| b) |
LEI |
5493000HZTVUYLO1D793 |
|||
| 3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
| a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
|||
| b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan |
|||
| c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
|
£14.0080 |
163 |
|
||
|
|
|
|
|
||
| d) |
Aggregated information
|
N/A (single transaction)
|
|||
|
Aggregated volume Price |
|
||||
| e) |
Date of the transaction |
2021-10-11 |
|||
| f) |
Place of the transaction
|
London Stock Exchange (XLON) |
|||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.